

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> A61K 31/765, 9/127, 47/32 // (A61K 31/765, 31:00)		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/42962</b> <b>(43) International Publication Date:</b> 20 November 1997 (20.11.97)
<b>(21) International Application Number:</b> PCT/CA97/00319 <b>(22) International Filing Date:</b> 9 May 1997 (09.05.97)  <b>(30) Priority Data:</b> 60/017,106 9 May 1996 (09.05.96) US		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(71)(72) Applicants and Inventors:</b> BERGERON, Michel, G. [CA/CA]; 2069 Brûlard, Sillery, Quebec G1T 1G2 (CA). DESORMEAUX, André [CA/CA]; 7640 de Beauchastel, Neufchatel, Quebec G2C 1Y1 (CA). TREMBLAY, Michel [CA/CA]; 7073 rue Des Brumes, Neufchatel, Quebec G2C 1P3 (CA).  <b>(74) Agents:</b> DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).			
<b>(54) Title:</b> FORMULATION FOR USE IN THE PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV			
<b>(57) Abstract</b> <p>This invention relates to formulations comprising film-forming components capable of forming <i>per se</i> a physical barrier to pathogens. Thermoreversible gels such as poloxamers are particularly preferred for that use. The film-forming formulations may further comprise microbicides, spermicides or any other drug, which choice is guided by the pathogen, organism or the disease to be inactivated or treated. The formulations are therefore efficient as a physical, and optionally, as a chemical or pharmacological barrier as well as usable as a sustained drug-release system at the locus of administration. A part of the drug may also be entrapped in liposomes or other drug carriers. These formulations are intended for use in the prevention of sexually transmitted diseases, as well as in the treatment of infections, cancer, inflammation or any disease or state which requires a pharmacological treatment. Formulations are applicable to mucosae, skin and eye, for example.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TITLE OF THE INVENTION**

FORMULATION FOR USE IN THE PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV

5    **Field of the invention**

This invention relates to formulations comprising film-forming components, particularly to topical formulations, and more particularly to topical formulations i) to prevent the transmission of pathogens through mucosae and/or skin, more particularly those useful to prevent the sexual transmission of human immunodeficiency virus and other sexually transmitted diseases, ii) to treat lesions of mucosae and/or skin caused by pathogens or any other disease and iii) to prevent and/or treat any other pathogen of mucosae and/or skin including any infection, cancer, inflammatory process or any other disease.

15    **Background of the invention**

As there is no truly effective treatment or vaccine against AIDS, preventive measures are the only tools that can presently reduce the transmission of human immunodeficiency virus (HIV). The consistent and careful use of appropriate condoms represents an effective barrier to prevent HIV transmission. However, condoms should be used for almost all sexual intercourses to significantly reduce the probability of acquiring infection. In Africa, the most intensive prevention programs were only able to increase condom use to approximately 70% of all sexual intercourses in female prostitutes. Thus, doubts arise about the possibilities of condom promotion in controlling the AIDS epidemic in high risk groups. In situations where heterosexual transmission of HIV is important, preventive measures that depend on female behaviour would be an additional tool to control the epidemic. Since the women's compliance to preventive interventions for sexually transmitted diseases (STDs) is superior to that of men, regular use of such a preventive measure may be possible. This is reinforced by the fact that the introduction of different products into the vagina is a common practice in developing countries. Such a protective tool may also be useful in male homosexual relations as it could provide additional protection under the control of the receptive partner.

30    The development of microbicides to prevent the sexual transmission of HIV in humans constitutes actually one of the most important research areas in the field of HIV prevention. One of the major difficulties with this approach is that drugs used to control HIV transmission, including spermicides such as nonoxynol-9, have been shown to induce local inflammation and ulcerations which might favour the entry of

HIV. As the number of individuals infected with HIV is growing dramatically throughout the world, there is an urgent need to develop active products and/or vehicles that could reduce the transmission of HIV with minimal mucosal irritation and minimal effects on the vaginal flora and pH. The use of gel formulations of microbicides or any other drug, 5 that could be topically applied to the vaginal, cervical and/or ano-rectal mucosae of humans, represents a convenient strategy to achieve such a goal. The microbicides or any other drug can be entrapped into the gel formulations either as free or encapsulated into drug carriers such as liposomes, nanoparticles or cyclodextrins. Such microboidal gels could prolong the local microboidal activity, eliminate local 10 irritation and reduce systemic side effects of incorporated active agents.

Herpes simplex virus type 2 (HSV-2) is one of the most common STDs. An animal model of intravaginal HSV-2 infection represents an interesting approach to evaluate the efficacy of our gel formulations to prevent the sexual transmission of that pathogen. Another important herpes virus infection is herpes simplex virus type 1 15 (HSV-1) which is a neurotropic virus that infects principally the neuroectodermal tissues including the skin, the peripheral nerves and the central nervous system. Recurrent HSV-1 cutaneous infections are frequently observed in immunocompromised patients. Zoster is clinically characterized by an unilateral dermatome distribution and by the occurrence of neuralgic pain both as a result of 20 peripheral nerve involvement. Although, it is a mild disease, cutaneous HSV infections can be troublesome, especially for patients with frequent episodes. Foscarnet and acyclovir are both antiviral agents active against all types of herpes viruses. However, the currently available treatments, either topical or systemic, have only a limited 25 efficacy particularly for the treatment of symptomatic recurrent herpes. Therefore, there is a need to develop new topical formulations of antiviral agents which could improve the efficacy of drugs.

Liposomes are microscopic vesicles composed of one or several lipid bilayers separated by aqueous compartments in which a variety of drugs can be incorporated. Numerous studies have shown an improved therapeutic index and a reduced toxicity 30 for drugs entrapped in liposomes. We have already demonstrated that the encapsulation of anti-HIV agents into liposomes allows high cellular penetration, good *in vitro* antiviral activity against HIV, efficient targeting of macrophage-rich tissues and a marked improvement of the pharmacokinetics of drugs (Désormeaux et al., 1994, AIDS 8:1545-1553; Makabi-Panzu et al., 1994, AIDS Res. Hum. Retroviruses 35 10:1463-1470; Dusserre et al., 1995, AIDS 9:833-841; Harvie et al., 1995, AIDS 9:701-707; Harvie et al., 1996, Antimicrob. Agents Chemother. 40:225-229). To our knowledge, liposome-encapsulated drugs have never been used to prevent the

mucosal transmission of infectious agents. When applied locally to mucosa or skin, liposomes are usually taken up by monocytes and macrophages and also by Langerhans cells which may capture and harbor HIV. Consequently, in contrast with free drugs, which tend to diffuse rapidly through the mucosa and reach the circulation, 5 the use of drugs within liposomes and incorporated into a gel formulation should concentrate the active agents within infected cells as well as within cells susceptible to HIV infection. Such drug delivery system is even more attractive as it was shown that liposomes are very well tolerated when given topically (Parnham and Wetzig, 1993, *Chem. Phys. Lipids* 64:263-274).

10 US Patent 5,292,516 describes gel formulations comprising poloxamers which are used as drug delivery systems. However, no mention is made in that reference that the gels themselves are physical barriers *per se* impeding permeation of pathogens therethrough.

15 The international patent publication WO 95/10268 describes a composition comprising poloxamer 407 gel (18% w/w) containing cysteamine to prevent HIV infection. This reference indeed teaches that poloxamer 407 gel can be used as a vaginal gel, but it does not suggest that the poloxamer itself might be used as a physical barrier to prevent the transmission of a pathogen and its permeation through the membrane of mucosa. Furthermore, this reference does not teach that the gel 20 formulation could act as a pharmacological barrier to prevent the infection of host cells. In addition, this reference does not show any *in vitro* and *in vivo* evidence that the gel formulation might be efficient to prevent the transmission of pathogens.

25 There is, therefore, still a need for a method and compositions for preventing transmission of pathogens through the membrane of mucosae and/or skin which compositions and method would result in the creation of a physical barrier to permeation of pathogens, and optionally in the further creation of a chemical or pharmacological barrier to pathogen transmission.

#### Summary of the invention

30 It is an object of the present invention to provide a method i) to prevent the transmission of pathogens through mucosae and/or skin, more particularly those useful to prevent the sexual transmission of human immunodeficiency virus and other sexually transmitted diseases, ii) to treat lesions of mucosae and/or skin caused by pathogens or any other disease and iii) to prevent and/or treat any other pathogen of mucosae and/or skin including any infection, cancer, inflammatory process or any 35 other disease.

It is an object of the present invention to provide formulations to prevent the transmission of pathogens through mucosae and/or skin, more particularly those useful to prevent the sexual transmission of human immunodeficiency virus and other sexually transmitted diseases. It is another object of the present invention to provide 5 formulations to treat lesions of the mucosae and/or skin. It is still another object of the invention to provide formulations to prevent and/or treat any other pathogen of mucosae and/or skin including any infection, cancer, inflammatory process or any other disease.

In preferred embodiments, the above method and formulations are effective to 10 prevent the transmission of STDs, more particularly HIV, by acting as a physical, chemical and/or pharmacological barrier. The physical barrier comprises a film-forming component which is applied to the surface of mucosa or skin, preferably in the form of gel, cream or ointment. Most preferably, a thermoreversible gel is applied in a liquid form, spreads on this surface and forms a semi-solid coating after it reaches the 15 temperature of this body surface. In a more preferred embodiment, the thermoreversible gel is composed of poloxamer 407. Similar polymers like poloxamines can also be used. The semi-solid gel alone acts as a mechanical (physical) barrier which blocks access of either free or intracellular pathogen to the mucosa or skin. The chemical and/or pharmacological barrier comprises a microbicide, 20 a spermicide and/or any other drug. For the purpose of the invention, the term "microbicide" is intended to cover any agent effective against pathogens. A chemical barrier comprises free microbicide(s), spermicide(s) and/or any other drug entrapped in gel, which chemically destroys pathogens coming into contact with the mucosa or skin and also reduces or eliminates toxicity of the microbicides, spermicides and/or 25 other drug to epithelial cells. Microbicides, spermicides and/or any other drug may be released from the gel or they may get in situ on pathogens or infected cells. In a more preferred embodiment, the chemical barrier is intended to be used in gel applicable on the vaginal, cervical and/or ano-rectal mucosae, and is a compound such as nonoxynol-9. A pharmacological barrier may comprise a microbicide, a spermicide 30 and/or any other drug effective against the pathogen such as an adsorption inhibitor which prevents pathogen's entry into a target cell, an inhibitor for an enzyme necessary for the replication of the pathogen or a metabolic poison for the pathogen. In a more preferred embodiment, the pharmacological barrier is intended to be used in gel applicable on the vaginal, cervical and/or ano-rectal mucosae to prevent the sexual 35 transmission of HIV and comprises inhibitors of HIV protease and reverse transcriptase (alone or in combination). These inhibitors are preferably encapsulated within drug carriers such as liposomes, nanoparticles or cyclodextrins, which encapsulation results in the concentration of the inhibitors within the HIV target host cells, preventing either

the production of infectious viral particles or infection of uninfected cells. If infected cells in sperm can reach the mucosa, the gel formulation of anti-HIV agents could prevent HIV infection of host cells, such as macrophages, lymphocytes, Langerhans and M cells.

5        In a preferred embodiment, the gel formulation is composed of poloxamer 407. In a more preferred embodiment, the poloxamer 407 concentration is 19.5% (w/w). In another preferred embodiment, the gel formulation is composed of poloxamer 407 (19.5% w/w) and contains nonoxynol-9 as microbicide. In another preferred embodiment, the gel formulation is composed of poloxamer 407 (19.5% w/w) and 10 contains liposomes composed of distearoylphosphatidylcholine (DSPC): distearoylphosphatidylglycerol (DSPG) in a molar ratio of 10:3 within which 2'-3'-dideoxyinosine (ddl) is entrapped as antiviral drug. In another preferred embodiment, the gel formulation is composed of poloxamer 407 (19.5% w/w) and contains liposomes composed of DSPC: DSPG: distearoylphosphatidylethanolamine- 15 polyethylene-glycol (DSPE-PEG) in a molar ratio of 10:3:1.45 within which ddl is entrapped as antiviral drug. In another preferred embodiment, the gel formulation is composed of poloxamer 407 (19.5% w/w) and contains liposomes composed of dipalmitoylphosphatidylcholine (DPPC): dicetylphosphate (DP): cholesterol (CHOL) in a molar ratio of 4:1:5 within which 2'-3'-dideoxycytidine (ddC) is entrapped as antiviral 20 drug. Yet in another preferred embodiment, the gel formulation is composed of poloxamer 407 (19.5% w/w) and contains liposomes composed of DPPC:dipalmitoylphosphatidylglycerol (DPPG) in a molar ratio of 10:3 within which foscarnet is entrapped as antiviral drug.

25        In another more preferred embodiment, the gel formulation is composed of poloxamer 407 (18% w/w). In another preferred embodiment, the gel formulation is composed of poloxamer 407 (18% w/w) and contains foscarnet as a microbicide. In still another preferred embodiment, the gel formulation is composed of poloxamer 407 (18% w/w) and contains acyclovir as a microbicide. In still another preferred embodiment, the gel formulation is composed of poloxamer 407 (18% w/w) and 30 contains liposomes composed of DPPC:DPPG in a molar ratio of 10:3 within which foscarnet is entrapped as antiviral drug. In still another preferred embodiment, the gel formulation is composed of poloxamer 407 (18% w/w) and contains liposomes composed of DPPC:DPPG in a molar ratio of 10:3 within which acyclovir is entrapped as antiviral drug.

Concentrations of poloxamer may be varied upon conditions such as the liquid/gel transition temperature, the physical properties sought for the gel and the pH used in the making of the formulations.

The gel formulations are to be used for coating different types of mucosae such as vaginal, cervical, ano-rectal, eye, mouth, nose, or skin to prevent the penetration of pathogens such as viruses, bacteria, fungi, parasites, ectoparasites and mycoplasmas. Furthermore, the gel formulations can be injected into the eye for ophthalmic uses. The gel formulations can be combined with microbicides and/or antimicrobials and/or chemotherapeutic agents and/or antiinflammatory agents and/or any other drug and/or spermicides and/or liposomes (or other drug carriers). Furthermore, microbicides and/or spermicides can be combined with liposomes (or other drug carriers) to prevent or treat any disease of mucosae and/or skin. In addition, our gel and/or liposome (or other drug carriers) formulations can also be used as carriers of vaccines against infections caused by pathogens or any disease.

15 **Brief description of the drawings**

Figure 1 shows the cytotoxicity of the poloxamer 407 gel (19.5 % w/w) when applied to human cervical (ME-180) and colon (HT-29) epithelial cells.

Figure 2 represents the viability of human cervical cells following incubation with different concentrations of nonoxynol-9 either as free drug or incorporated into the poloxamer gel (19.5 % w/w).

Figure 3 represents the efficacy of the poloxamer 407 gel (19.5 % w/w) as a physical barrier against HIV.

Figure 4 shows the efficacy of the poloxamer 407 gel (19.5 % w/w) to prevent infection of Sup-T1 cells with HIV.

25 Figure 5 shows the effect of daily intravaginal application for two weeks of poloxamer gel (19.5 % w/w) and/or nonoxynol-9 to rabbits.

Figure 6 shows the corresponding histopathology of cervix after daily intravaginal application for two weeks of poloxamer gel (19.5 % w/w) and/or nonoxynol-9 to rabbits.

30 Figure 7 represents the efficacy of the poloxamer gel (19.5 % w/w) to prevent the genital transmission of an *Herpes simplex virus* type 2 in mice.

Figure 8 shows the efficacy of poloxamer gel alone (18% w/w) and of the gel containing 3% foscarnet to treat HSV-1 cutaneous lesions in mice.

35 Figure 9 represents time evolution of the mean lesion score of HSV-1 infected mice without any treatment or treated with the poloxamer gel (18% w/w) alone or with the gel containing 3% foscarnet.

### Detailed description of the invention

The present invention is described herein below by way of specific examples and appended drawings, which purpose is to illustrate the invention rather than to limit its scope.

#### 5 Gel formulations

Poloxamer 407 is a block copolymer of polyoxyethylene and polyoxypropylene in a 7:3 weight ratio with an average molecular weight of 12500. One important characteristic of this block copolymer is its ability to form a thermoreversible gel. The transition from the liquid state at low temperature to the gel state at body temperature 10 (the phase transition temperature being dependent, in part, on the concentration of the gel and on the ionic strength) allows a number of interesting medical applications including topical applications. Such characteristic is of prime importance because when applied topically in their fluid state to the mucosa, the gel formulations will form an artificial barrier which could resist to biological fluids. Because of the extremely low 15 toxicity and irritancy of our gel formulations, they represent an attractive approach for topical drug delivery systems. Details for the preparation of the gel formulations are provided in Example 1. This invention covers gel formulations of poloxamer 407 of any suitable concentration (w/w), and more particularly those between about 10 and 50 % w/w. This invention also covers any other film-forming component, gel, cream, 20 ointment or thermoreversible substance including other poloxamers, poloxamines or chemicals.

#### Microbicides, spermicides and other drugs

Any microbicide which is effective against pathogens (viruses, bacteria, fungi, parasites, ectoparasites and mycoplasmas) is under the scope of this invention. 25 Particularly those which are effective against HIV, HSV or other microbial diseases, and more particularly sexually transmitted diseases are preferred. Included in this class are spermicides (such as nonoxynol-9, benzalkonium chloride and menfegol), inhibitors of HIV adsorption (such as dextran sulfate), inhibitors of HIV protease (such as saquinavir, indinavir and ritonavir), inhibitors of HIV reverse transcriptase (such as AZT, ddC, ddl, 3TC and foscarnet) and other antivirals (such as ribavirin, acyclovir and ganciclovir) and any antimicrobial agent including antibiotics, antifungals, antivirals, 30 antiparasitics and chemotherapeutic agents, antiinflammatory agents, antitoxins, immunotherapeutic agents to control any disease of mucosae and/or skin. It is important to mention that microbicides and/or spermicides can be used alone or in combination with any other drug. This invention also covers any combination of gels 35 and/or microbicides and/or spermicides.

Liposomes

In liposome-based products, we already showed that, for targeting HIV infected tissues, it is necessary to use liposome bilayer characteristics which allow high efficiency of drug encapsulation as well as reduced leakage of entrapped drug to take advantage of the ability of liposomes to deliver high concentrations of drugs into cells. Based on previous studies performed in our laboratory, these requirements can be obtained by using liposomes composed of i) a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol (in a molar ratio ranging between 10:1 and 1:1) wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length or ii) a mixture of diacylphosphatidylcholine:dicetylphosphate:cholesterol, wherein the acyl chains of phosphatidylcholine are either saturated or unsaturated and have between 14 and 18 carbon atoms in length. However, it is deemed that a family of liposomal formulations can be easily derived therefrom, without affecting the valuable properties thereof. Therefore, this family of compounds comprises other acyl chains of given phospholipid formulations that have been tested in the practice.

The liposomes of the present invention also include sterically stabilized liposomes, defined herein as, liposomes which are modified by the incorporation of polymers, such as poloxamers and poloxamines, or of amphipathic lipids derivatized with a polymer, such as DSPE-PEG or dioleoylphosphatidylethanolamine-PEG (DOPE-PEG), or of any molecule which prolong the circulation time of liposomes. The liposomes of the present invention also include immunoliposomes, defined herein as, liposomes which are modified by the coupling of antibody molecules which enhance the targeting of specific cells. The liposomes of the present invention also include pH-sensitive liposomes, heat-sensitive liposomes, target-sensitive liposomes and any other types of liposomes that could be used for this purpose. This invention also covers any combination of gels and/or microbicides and/or spermicides and/or any other drug and/or liposomes and/or vaccines.

The preparation of liposomes in the present invention can be done by a variety of techniques such as those described in the literature (e.g. Szoka and Papahadjopoulos, 1980, Ann. Rev. Biophys. Bioeng. 9:467-508; Nassander et al., 1990, Liposomes in biodegradable polymers as drug delivery systems, p.261-338). Formulations of liposomes of the present invention include those having a mean particle diameter of any size prepared with any drug/lipid molar ratio. Incorporation of drugs into liposomes can be achieved by one or more methods of active and/or passive loading such as those described in the literature (e.g. Mayer et al., 1986, Chem. Phys. Lipids 40:333-345).

The following examples are intended to demonstrate the preparation of gel formulations that could be very efficient for the prevention of the sexual transmission of HIV and for the treatment of cutaneous lesions caused by herpes virus infections, but are in no way intended to limit the scope thereof. Our gel formulations could be applied to prevent the transmission of several other sexually transmitted diseases such as those due to viruses (herpes simplex virus, human papillomavirus, human immunodeficiency virus, *Molluscum contagiosum*, cytomegalovirus, Epstein-Barr virus, hepatitis A, B, C and ), bacteria (*Neisseria gonorrhoeae*, *Treponema pallidum*, *Chlamydia trachomatis*, *Gardnerella vaginalis*, *Calymmatobacterium granulomatis*, *Haemophilus ducreyi*, *Streptococcus pyogenes*, *Helicobacter jejuni*, *Prevotella bivius*, *enterococcus* spp., *peptococcus* spp., *Bacteroides* spp., *Mobiluncus*, *enterobacteriaceae*, such as *Shigella* spp., *Salmonella* spp. and *Pseudomonas aeruginosa*), mycoplasmas (*Mycoplasma hominis*, *Ureaplasma urealyticum*, *Mycoplasma genitalium*), parasites (*Trichomonas vaginalis*, *Entamoeba histolytica*, *Cryptosporidium*, *Enterobius vermicularis*, *Giardia lamblia*, *Mobiluncus*), fungi (*Candida albicans*, *Candida* spp., *Torulopsis glabrata*, *Dermatophytes*) and ectoparasites (*Phthirus pubis*, *Pediculus humanus*, *Pediculus capitis*, *Sarcoptes scabiei*). In addition, the microbicidal gels could also be applied to the skin of health professionals who may get accidentally exposed to HIV or any other pathogen. Beside prevention of the transmission of infections, they may be used to treat these infections and to prevent or cure any pathology of mucosae and/or skin including cancer, inflammatory process or any other disease process.

Even though the description of this invention is limited to specific cases, any film-forming component and/or microbicide and/or spermicide and/or any other drug and/or liposomes (or other drug carriers) or any combination of the above are considered as potential candidates for the development of these topical presentations and are under the scope of this invention. The formulations also include any film-forming component and/or microbicide and/or spermicide and/or any other drug and/or liposomes (or other drug carriers) or any combination of these products at any suitable concentration.

### EXAMPLE 1

#### Preparation of the microbicidal gels

The thermoreversible gels are prepared by adding an appropriate volume of distilled water, acetate buffer (0.2 M, pH 4.6), phosphate buffer (0.2 M, pH 6), HEPES buffer (0.02 M, pH 7.2) or any other suitable aqueous solution to the poloxamer 407 to obtain the desired ratio (w/w). The solution is then stirred at 4°C to ensure complete dissolution and is let stand to allow stabilization of the gel matrix. An appropriate

amount of microbicides, either as free or entrapped into drug carriers, are then added to the cold polymer solution.

#### Examples involving our gel formulations

For the purpose of testing the *in vitro* toxicity of our gel formulations on cell lines, the solutions were prepared with a pH near neutrality, to be compatible with the conditions wherein cell lines are viable. The pH can be adjusted to meet the requirements of each target tissue to be coated with the present formulations. For instance, if a formulation is to be used to coat vaginal mucosa, a slightly acidic pH will be used. The percentage of polymer may be adjusted accordingly to obtain an adequate transition temperature from liquid to solid state.

#### Drug release experiments

The poloxamer gel could act as a sustained-drug release system which prolong the local microbicidal activity of the incorporated active agents. We have studied the release of antiviral agents (AZT, ddC, ddl, foscarnet, acyclovir) from our poloxamer gel formulations using radiolabelled drugs and a diffusion cell made of two compartments separated by a dialysis membrane. Results showed that the release of drugs was increased at body temperature when compared to 4°C, although the viscosity of the gel is increased (data not shown). This is explained by the creation of large openings in the intermicellar network of the gel at high temperature which in turn increase the release of the incorporated active agents.

#### *In vitro* toxicity experiments

The cytotoxicity of the poloxamer 407 gel formulation (19.5% w/w) was evaluated in both human cervical (ME-180) and colon (HT-29) epithelial cells. Briefly, a semi-confluent monolayer of cells has been deposited on cell culture inserts in 24-well plates containing McCoy 5a medium and the gel was deposited on top of the cells. After an incubation of 24 hours, cells were washed with PBS to remove the gel and 500 µl of fresh medium with 50 µl of MTS solution (2 mg/ml in PBS) were added to each well. Plates were then incubated at 37°C in a CO<sub>2</sub> incubator for 1 hour. The medium was then transferred into a 96-well plate and the optical density was read at 420 nm. Results showed that our gel formulation is non-cytotoxic when applied on the cell lines (figure 1).

Figure 2 shows the viability of human cervical cells following incubation with different concentrations of nonoxynol-9 either as free drug or incorporated into the poloxamer gel (19.5% w/w). As expected, nonoxynol-9 was highly toxic to the human cervical cells in a dose-dependent manner with a toxicity starting at 150 µg/ml. Of

prime interest, we have demonstrated that the incorporation of that spermicide into our gel formulation was not toxic under the same experimental conditions.

#### Efficacy of the gel as a physical barrier against HIV

5 The ability of the poloxamer gel to block the passage of HIV-1 has also been monitored. In brief, cell culture inserts (0.4  $\mu$ m membrane pore size) were placed in 24-well plate. Thereafter, above the membrane, 100  $\mu$ l of the gel (19.5 % w/w in pH 7.2 HEPES buffer) was added prior to the addition of HIV-1<sub>IIIB</sub> (5000 pg of p24). Diffusion of viral particles through the gel and the membrane was evaluated over time by monitoring levels of p24 with a commercial enzymatic assay (Organon Teknika, 10 Durham, NC). Results from this set of experiments indicate that the gel acts as a physical barrier to block the passage of HIV-1 particles by greatly reducing the amount of viral particles passing through the gel and membrane (figure 3).

#### Efficacy of the gel to prevent HIV infection of T cells

15 Similar type of studies were carried out by adding at the bottom of each well an indicator cell line known to be highly susceptible to HIV-1 infection. The human CD4-positive T lymphoid cell line Sup-T1 was used for these experiments. Briefly, Sup-T1 cells were first seeded in 24-well plate ( $1.25 \times 10^5$  cells/well). Next, cell culture inserts were placed in each well and, above the membrane, 100  $\mu$ l of the gel (19.5 % w/w in pH 7.2 HEPES buffer) was added prior to the addition of HIV-1<sub>IIIB</sub> (multiplicity 20 of infection of 0.01; infectious viral particle per target cell). After 48 h of incubation at 37°C, inserts were removed and cells were washed to remove uninternalized viruses. Cells were maintained in complete culture medium and reverse transcriptase activity was determined in cell-free culture supernatants. As depicted in figure 4, virus replication is abolished by the presence of the gel. Results from the above experiments 25 thereby suggest that the effect of the gel is either by physically blocking HIV particles and/or by negatively affecting viral infectivity. This experiment was repeated several times and gave similar results.

#### In vivo toxicity experiments

30 Studies have been performed to evaluate the tolerance and toxicity of the poloxamer 407 gel (19.5% w/w) when applied locally once daily for two weeks to the vaginal and cervical mucosae of New Zealand rabbits. The gel was applied in its fluid state to allow a good penetration into the irregularly shaped surfaces of the mucosae. Biopsies of the vaginal and cervical mucosae were performed on days 0, 4, 7 and 14 35 for histological examinations. Figure 5 shows the effect of intravaginal application of gel and/or nonoxynol-9 on the vaginal and cervical mucosae of rabbits. Results showed that animals treated with the gel alone did not show signs of toxicity to vaginal

and cervical mucosae (figure 5b) as compared to control (figure 5a). In contrast, nonoxynol-9 at a dose of 125 mg was very toxic as evidenced by the presence of epithelial disruption, irritation, necrosis and bleeding (figure 5c). Such toxicity induced by nonoxynol-9 might favour the entry of pathogens. However, the incorporation of 5 nonoxynol-9 into the gel completely resolved the toxicity of the spermicide (figure 5d).

Figure 6 shows the corresponding histopathology of cervix after intravaginal application once daily for two weeks of poloxamer gel (19.5% w/w) and/or nonoxynol-9. No major histology modifications was observed to the cervical mucosa of rabbits after the application of the gel alone (figure 6b) when compared to control (figure 6a). In 10 contrast, optic microscopic examination of the cervical mucosa treated with nonoxynol-9 showed a large accumulation of eosinophiles in the sub-mucosa and induce a major loss of integrity of the epithelial cells (figure 6c). On the other hand, application of the same amount of spermicide incorporated into the gel showed no signs of toxicity (figure 6d) and was comparable to that observed with the gel alone.

15 In vivo efficacy experiments

The efficacy of the poloxamer gel (19.5% w/w) to prevent the genital transmission of HSV-2 was evaluated in mice. In brief, female Balb/c mice aged 4 weeks were used for this study. To increase susceptibility of mice to herpes, 2.5 mg of progesterone (Depo-Provera) was administered subcutaneously to each mouse 7 days prior to and on the day of inoculation with HSV-2. Anesthetized mice were 20 inoculated with 10  $\mu$ l of  $2.4 \times 10^7$  pfu/ml of HSV-2 strain 333 after swabbing the vagina with a calcium alginate thin tipped swab premoistened with culture medium. To determine the efficacy of the poloxamer gel (19.5% w/w) to block the herpes infection, 10  $\mu$ l of the gel was delivered with a pipette tip into the vagina a few minutes prior to 25 the inoculation. The pipette tip was moved in and out four times to simulate stirring action of sexual intercourse while being cautious not to cause any bleeding. Four days post-infection, control infected animals demonstrated perineal oedema and redness and by 6 to 9 days, most of them died of encephalitis (figure 7). In contrast, no animal pretreated with the gel died (i.e. 100% survival) 9 days post-infection. These results 30 clearly indicate that the use of our gel preparation could represent an innovative preventive measure to reduce the sexual transmission of STDs (including HIV).

The efficacy of poloxamer gel (18% w/w) alone and of the gel containing 3% foscarnet to treat HSV-1 cutaneous lesions in mice has also been investigated. In brief, hairless mice (SKH1, 35-42 days old) were anesthetized by intraperitoneal injection of 35 a ketamine (70 mg/kg)/xylazine (11.5 mg/kg) solution. The virus (HSV-1, strain F; isolated from human facial vesicles; ATCC VR-733) was inoculated on the lateral side

of the body in the lumbar skin area. The skin was scratched 6 times with a 27 gauge needle held vertically in a crossed hatched pattern. 50  $\mu$ l of viral suspension ( $1.5 \times 10^7$  pfu/ml) was then applied onto the scratched skin area. The viral suspension was rubbed on the skin with a cotton tipped applicator saturated with the culture medium in which the virus was suspended. The scarified area was protected with a corn cushion (Schering Plough) which was maintained on the mice body with surgical tape. Mice develop vesicular cutaneous rash which rapidly coalesce to form a 4-5 mm wide band extending from the spine to the ventral midline of the affected dermatome similar to zoster-like infections. Virus spreads eventually to the central nervous system and causes encephalitis and ultimately death.

At 24 hours post-infection, mice were treated three times daily for 4 days with the gel alone or with the gel containing 3% foscarnet. Briefly, the surgical tape closing the aperture of the corn cushion was removed and the scarified skin area was cleaned using a cotton tipped applicator saturated with cold water. 15  $\mu$ l of the gel with or without foscarnet was applied onto the scarified area. The aperture of the corn cushion was then closed again with surgical tape. Mice were examined twice daily for survival as well as for the evaluation of the lesion score according to the criteria presented in table 1.

Table 1: Criteria for scoring herpetic cutaneous lesions

	Score	Clinical manifestation
20	0	No sign of infection
	1	Infection visible at the inoculation site only
	2	Infection visible at the inoculation site along with swelling, crust and erythema
25	3	Infection visible at the inoculation site along with lesions forming away from inoculation site. Erythema in about half-body
	4	Vesicular rash about half-body but not yet confluent
	5	Vesicular rash totally confluent but not yet necrotic or ulcerated
	6	Vesicular rash totally confluent but also necrotic or ulcerated. Hind limb paralysis, bloating and death
30		

Figure 8 shows the survival of mice infected cutaneously with HSV-1, without any treatment, treated with the poloxamer gel (18% w/w) alone or with the gel containing 3% foscarnet. In untreated mice, the lethality of the infection was 33%. In mice treated with gel alone, we observed a mortality of 50% suggesting that the gel exert no therapeutic effect by itself in this herpes model. However, for mice treated

with the poloxamer gel containing 3% foscarnet, all mice survived the infection demonstrating a good efficacy of the drug when incorporated into the gel.

Figure 9 shows the time evolution of mean lesion score of mice infected cutaneously with HSV-1, without any treatment, treated with the poloxamer gel (18% w/w) alone and with the gel containing 3% foscarnet. In untreated mice, no pathological signs of cutaneous infection were visible during the first 4 days post-infection. On day 5, herpetic lesions began to appear in some mice in the form of small vesicles distant from the inoculation site. On day 6, almost all untreated mice developed herpetic skin lesions. Maximal mean lesion score was observed on day 8.

Mean lesion score decreased on days 12 to 16 because of spontaneous regression of lesions in some mice. In mice treated with the gel alone, we observed a pattern largely similar to that seen with untreated mice suggesting that the gel alone has no therapeutic effect on the development of herpetic skin lesions. Of prime importance, we observed a marked reduction of mean lesion score in mice treated with the gel containing 3% foscarnet compared to untreated mice demonstrating a good efficacy of the drug incorporated into the gel. Therefore, the formulations properly performed drug delivery. Since they have also been shown to inhibit permeation of pathogens from an infected environment to a non-infected one (previous example with HSV-2), the present formulations have a dual purpose to act as drug delivery systems and as a barrier to contagion from external pathogens or to contagion from an infected subject to non-infected ones. Any adjuvant medication may be added to the formulations. For example, antihistaminics could be added to a formulation comprising a poloxamer and acyclovir when the intended use is for treating Herpes virus infections, where inhibition of itching and scratching is desirable to provide more comfort to the patient and to avoid spreading of infection.

This invention has been described hereinabove and it will be readily apparent to the skilled reader that variations could be brought to the embodiments described, without departing from the above teachings. These variations are under the scope of this invention, as defined in the appended claims.

**WHAT IS CLAIMED IS:**

1. A gel formulation to prevent diseases caused by transmittable pathogens in a patient comprising a gel component capable of spreading and forming a protective layer on patient's skin or mucosa, said gel formulation being capable of preventing the 5 passage of said pathogens from an infected environment through a non-infected environment with regard to said patient's skin or mucosa.
2. A gel formulation according to claim 1, wherein said gel component is thermoreversible.
3. A gel formulation according to claim 2, wherein the thermoreversible gel 10 comprises a poloxamer.
4. A gel formulation according to claim 3, wherein the poloxamer is poloxamer 407.
5. A gel formulation according to claim 4 wherein poloxamer 407 is present in a concentration of about 10 to 50% (w/w).
- 15 6. A gel formulation according to claim 5 wherein poloxamer 407 is present in a concentration of about 18% (w/w).
7. A gel formulation according to claim 5 wherein poloxamer 407 is present in a concentration of about 19.5% (w/w).
- 20 8. A gel formulation according to any one of claims 1 or 7 further comprising microbicide, antimicrobial, chemotherapeutic, antiinflammatory, antitoxin, immunotherapeutic, antihistaminic, spermicide agents, a vaccine against a patient's tissue component or against said pathogens, each alone or in combination.
- 25 9. A gel formulation according to claim 8 wherein the microbicide or spermicide is selected from the group consisting of dextran sulfate, saquinavir, indinavir, ritonavir, AZT, ddC, ddl, 3TC, foscarnet, ribavirin, acyclovir, ganciclovir, nonoxynol-9, benzalkonium chloride and menfegol.
10. A gel formulation according to claim 8 or 9 wherein at least a part of said microbicide or agents is entrapped in liposomes, nanoparticles or cyclodextrins.


11. A gel formulation according to claim 10 wherein at least a part of said microbicide or agents is entrapped in liposomes.
12. A gel formulation according to claim 11 wherein the liposomes comprise a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio 5 ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
13. A gel formulation according to claim 12 wherein the liposomes further comprises a polyethyleneglycol derivative of a diacylphosphatidylethanolamine.
14. A gel formulation according to claim 11 wherein the liposomes are 10 composed of a mixture of diacylphosphatidylcholine:dicetylphosphate:cholesterol, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.
15. A gel formulation according to claim 14 wherein the liposomes further comprises a polyethyleneglycol derivative of a diacylphosphatidylethanolamine.
16. A gel formulation according to claim 12 wherein the liposomes are 15 composed of distearoylphosphatidylcholine: distearoylphosphatidylglycerol in a molar ratio of 10:3 and the entrapped drug is ddl.
17. A gel formulation according to claim 13 wherein the liposomes are 20 composed of distearoylphosphatidylcholine: distearoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:1.45 and the entrapped drug is ddl.
18. A gel formulation according to claim 14 wherein the liposomes are composed of dipalmitoylphosphatidylcholine: dicetylphosphate:cholesterol in a molar ratio of 4:1:5 and the entrapped drug is ddC.
19. A gel formulation according to claim 12 wherein the liposomes are 25 composed of dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 and the entrapped drug is foscarnet.
20. A gel formulation according to claim 11 wherein the liposomes are 30 conventional, sterically stabilized liposomes, immunoliposomes, pH-sensitive liposomes, heat-sensitive liposomes or target-sensitive liposomes.

21. A gel formulation according to any one of claims 1 to 20 which is to be applied on different types of mucosae comprising vaginal, cervical, ano-rectal, eye, mouth, nose mucosae, or skin or is to be injected into the eye for ophthalmic use.

5 22. A method of preventing the transmission of pathogens through mucosae or skin, which comprises the steps of applying a gel formulation as defined in any one of claims 1 to 21 to the skin or mucosae of a patient susceptible to infection by said pathogens.


10 23. A method of treating a disease affecting skin or mucosae while avoiding transmission of pathogens therethrough, which comprises the step of applying a gel formulation as defined in any one of claims 7 to 20 to the skin or mucosa of a patient in need for such a treatment.

1/9




Cellular viability (% of control)


2/9




3/9




4/9




5/9




6/9






8/9



9/9



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 97/00319

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/765 A61K9/127 A61K47/32 // (A61K31/765, A61K31:00)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 10268 A (THOENE JESS G) 20 April 1995 cited in the application see page 2, line 18-31 see page 3, line 3-8 see page 16, line 25-41	3-8,10, 21-23
Y	---	3-23
X	US 5 292 516 A (VIEGAS TACEY X ET AL) 8 March 1994 cited in the application see column 6, line 68 - column 7, line 72 see column 10; examples 2,3	3-10, 21-23
Y	---	3-23
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

2.

Date of the actual completion of the international search

5 August 1997

Date of mailing of the international search report

28.08.97

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Herrera, S

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/CA 97/00319

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 03157 A (POLI IND CHIMICA SPA ; POLI STEFANO (IT); MAILLAND FEDERICO (IT); M) 17 February 1994 see page 6, line 25-29 see page 11, line 30 - page 12, line 10	3-5,8, 10,11, 21-23
Y	---	6,7,9, 12-20
X	EP 0 525 655 A (POLI IND CHIMICA SPA) 3 February 1993 see page 2, line 1	3,4,10, 11
Y	see claims 1-6	5-20
Y	FR 2 660 192 A (POLI IND CHIMICA SPA) 4 October 1991 see page 1, line 1-5 see page 7; example 3 see claims 1-6	10-20
	-----	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 97/00319

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: 1 - 2 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
The subject-matter of Claims 1 and 2 is not defined as a solution (by means of technical features) of a posed problem, but as the problem it self. This cannot be considered as an invention. Therefore these claims have not been searched.
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00319

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510268 A	20-04-95	AU 7931094 A CA 2173964 A US 5646189 A	04-05-95 20-04-95 08-07-97
US 5292516 A	08-03-94	US 5593683 A CA 2040460 A,C DE 69124416 D EP 0455396 A JP 4225914 A	14-01-97 02-11-91 13-03-97 06-11-91 14-08-92
WO 9403157 A	17-02-94	IT 1255460 B AT 135566 T CA 2141026 A DE 69301920 D DE 69301920 T EP 0652744 A ES 2085166 T	02-11-95 15-04-96 17-02-94 25-04-96 08-08-96 17-05-95 16-05-96
EP 0525655 A	03-02-93	IT 1250748 B AT 131725 T DE 69206913 D DE 69206913 T	21-04-95 15-01-96 01-02-96 15-05-96
FR 2660192 A	04-10-91	IT 1240354 B DE 4110779 A	07-12-93 02-10-91